Ineffective Use of Recombinant Activated Factor VII in Gastrointestinal Bleeding After Bone Marrow Transplantation
Author Information
Author(s): Phillip Eller, Christoph Pechlaner, Christian Wiedermann
Primary Institution: Medical University of Innsbruck
Hypothesis
Is recombinant activated factor VII an effective treatment for severe gastrointestinal bleeding in non-haemophilic patients after bone marrow transplantation?
Conclusion
The case suggests that recombinant activated factor VII is not effective for severe gastrointestinal bleeding after bone marrow transplantation.
Supporting Evidence
- Recombinant activated factor VII is effective in hemophilia but lacks evidence for non-haemophilic patients.
- The patient experienced severe gastrointestinal bleeding despite multiple treatments.
- After using rFVIIa, the patient still suffered from recurrent bleeding and ultimately died.
Takeaway
This study shows that a special medicine called rFVIIa didn't help a patient stop bleeding after a bone marrow transplant, even after trying it many times.
Methodology
Case report detailing the treatment and outcomes of a single patient with severe gastrointestinal bleeding after bone marrow transplantation.
Potential Biases
Publication bias may favor positive outcomes in existing literature.
Limitations
The findings are based on a single case report, which may not be generalizable.
Participant Demographics
45-year old Caucasian male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website